Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exact Sciences Corp EXAS

Healthcare Biotechnology
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test... see more

Recent & Breaking News (NDAQ:EXAS)

Exact Sciences to participate in August investor conference

PR Newswire August 1, 2022

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

PR Newswire July 8, 2022

Exact Sciences schedules second quarter 2022 earnings call

PR Newswire July 8, 2022

Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs

PR Newswire June 21, 2022

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022

PR Newswire May 27, 2022

Exact Sciences to participate in June investor conferences

PR Newswire May 27, 2022

Exact Sciences to participate in May investor conference

PR Newswire May 2, 2022

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

PR Newswire April 28, 2022

Exact Sciences Announces First Quarter 2022 Results

PR Newswire April 26, 2022

Exact Sciences schedules first quarter 2022 earnings call

PR Newswire April 8, 2022

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

PR Newswire March 7, 2022

Diversey Appoints Katherine S. Zanotti to its Board of Directors

GlobeNewswire March 1, 2022

Exact Sciences to participate in March investor conferences

PR Newswire February 28, 2022

Exact Sciences Announces Fourth Quarter 2021 Results

PR Newswire February 22, 2022

Exact Sciences schedules fourth quarter 2021 earnings call

PR Newswire February 8, 2022

Exact Sciences to participate in February investor conferences

PR Newswire February 1, 2022

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

PR Newswire January 18, 2022

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

PR Newswire January 9, 2022

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

PR Newswire January 9, 2022

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

PR Newswire January 9, 2022